Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Eribulin
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins